TrialLancet (London, England)2020

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.

Ivan Fan-Ngai Hung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.